HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions.

Abstract
Melatonin has potent cardioprotective properties. These actions have been attributed to its free radical scavenging and anti-oxidant actions, but may also be receptor mediated. Melatonin also exerts powerful anti-adrenergic actions based on its effects on contractility of isolated papillary muscles. The aims of this study were to determine whether melatonin also has anti-adrenergic effects on the isolated perfused rat heart, to determine the mechanism thereof and to establish whether these actions contribute to protection of the heart during ischaemia/reperfusion. The results showed that melatonin (50 microM) caused a significant reduction in both isoproterenol (10(-7) M) and forskolin (10(-6) M) induced cAMP production and that both these responses were melatonin receptor dependent, since the blocker, luzindole (5 x 10(-6) M) abolished this effect. Nitric oxide (NO), as well as guanylyl cyclase are involved, as L-NAME (50 microM), an NO synthase inhibitor and ODQ (20 microM), a guanylyl cyclase inhibitor, significantly counteracted the effects of melatonin. Protein kinase C (PKC), as indicated by the use of the inhibitor bisindolylmaleimide (50 microM), also play a role in melatonin's anti-adrenergic actions. These actions of melatonin are involved in its cardioprotection: simultaneous administration of L-NAME or ODQ with melatonin, before and after 35 min regional ischaemia, completely abolished its cardioprotection. PKC, on the other hand, had no effect on the melatonin-induced reduction in infarct size. Cardioprotection by melatonin was associated with a significant activation of PKB/Akt and attenuated activation of the pro-apoptotic kinase, p38MAPK during early reperfusion. In summary, the results show that melatonin-induced cardioprotection may be receptor dependent, and that its anti-adrenergic actions, mediated by NOS and guanylyl cyclase activation, are important contributors.
AuthorsSonia Genade, Amanda Genis, Kirsti Ytrehus, Barbara Huisamen, Amanda Lochner
JournalJournal of pineal research (J Pineal Res) Vol. 45 Issue 4 Pg. 449-58 (Nov 2008) ISSN: 1600-079X [Electronic] England
PMID18691357 (Publication Type: Journal Article)
Chemical References
  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Adrenergic Antagonists
  • Indoles
  • Maleimides
  • Oxadiazoles
  • Quinoxalines
  • Receptors, Melatonin
  • Tryptamines
  • luzindole
  • Colforsin
  • Nitric Oxide
  • Propranolol
  • Cyclic AMP
  • Protein Kinase C
  • p38 Mitogen-Activated Protein Kinases
  • Guanylate Cyclase
  • Melatonin
  • Isoproterenol
  • bisindolylmaleimide
  • NG-Nitroarginine Methyl Ester
Topics
  • Adrenergic Antagonists (pharmacology)
  • Animals
  • Colforsin (pharmacology)
  • Cyclic AMP (metabolism)
  • Guanylate Cyclase (metabolism)
  • Heart (drug effects, physiology)
  • Indoles (pharmacology)
  • Isoproterenol (pharmacology)
  • Male
  • Maleimides (pharmacology)
  • Melatonin (agonists, pharmacology)
  • Myocardial Infarction (pathology)
  • Myocardial Reperfusion Injury (prevention & control)
  • NG-Nitroarginine Methyl Ester (pharmacology)
  • Nitric Oxide (physiology)
  • Oxadiazoles (pharmacology)
  • Propranolol (pharmacology)
  • Protein Kinase C (metabolism)
  • Quinoxalines (pharmacology)
  • Rats
  • Rats, Wistar
  • Receptors, Melatonin (metabolism)
  • Tryptamines (physiology)
  • p38 Mitogen-Activated Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: